资源描述
0MNC 2023 2023 5 29|S0120521080001 1 010203040506 BMS CONTENTS ZXFUwPrMpMqRpRsRnQtMoPaQ8Q7NsQrRoMtQjMnNqNeRtQoOaQnNzRvPnOtMuOrNmM2 01 Pfizer3(PFE)-4 4 Ritlecitinib(JAK3/TEC)2023Q3 AA 2%AA FDA Olumiant baricitinib JAK JAK1 ritlecitinib JAK3 JAK 2b/3 AA AA JAK AA 10 2023 3 FDA 2022 Opzelura ruxolitinib JAK JAK ifidancitinib JAK1/3 brepocitinib JAK1/TYK2 cerdulatinib SYK/JAK JAK1 JAK2 Ritlecitinib JAK1/2 Talzenna+Xtandi(+PARP1/2+AR)2023Q3 Ritlecitinib AA 4 Elranatamab CD3/BCMA 2023Q3 RRMM BCMA Tecvayli teclistamab-cqyv Elranatamab CRS Elranatamab 1 24 Tecvayli 2 Tecvayli titration Tecvayli 40 Elranatamab 40 40 Abrysvo RSV 2023H2 60 2023H2 5/18 Adcom BCMA Antibodies and bispecifics for multiple myeloma:effective effector therapy Christopher Cipkar et al.(PFE)-4 5 Etrasimod S1PR UC 2023H2 UC 1L JAK 1L S1PR JAK UC 1020 UC Etrasimod Etrasimod(PFE)-4 6 Abrilada TNF-2023Q4 Amgen Abbvie Amjevita 2023/1/31 5 Amjevita 3472(0.4)7 Braftovi/Mektovi encorafenib/binimetinib BRAF/MEK1,2 2023Q4 Xtandi Enzalutamide AR 2023Q4(PFE)-4 7 02 Novartis8(NVS)Kisqali CDK4/6 ASCO NATALEE trial 3 3/27 8%3/265/15 23%NATALEE 70%2 Verzenio 23 Verzenio 1L 0S Kisqali OS CDK4/6 5 SeekingAlpha CDK4/6 Kisqali BIC 30 Pluvicto 177Lu-RLT PSMA 2023H2 mCRPC PSMAfore trial FDA 20 MNC 2426 12 9 Iptacopan CFB/B 2023H1 PNH FDA 4/27 92.2%iptacopan 24 2g/dL 97.6%2022 12 ASH 3 APPLY-PNH APPLY iptacopan SOC C5 2023H2 APPLAUSE-IgAN 3 IgAN iptacopan Iptacopan Narso Iptacopan APPLY 2023H2 APPEAR-C3G 3 30 D danicopan vemircopan 3 2 Remibrutinib LOU-064 BTK 2023 CSU 2024 20(NVS)10 03 Bristol-Myers Squibb11 BMS(BMY)Opdualag nivolumab/relatlimab PD-1/LAG3 NSCLC 2 2023 2024 1L 3 NCT05625399 2025 2L/3L+mCRC 3 NCT05328908 Repotrectinib ALK/TrkC/ROS1/TRKA Macrocyclic TKI ROS1+NSCLC(TRIDENT-1)TKI Opdualag 1L NSCLC 2 BMS Repotrectinib Peerview IO Repotrectinib 12 Abecma Idecabtagene vicleucel BCMA 3-5L MM KarMMa-3 PDUFA 2023/12/16 2023/2/10 KarMMa-3 51%/Carvykti Cartitude-4 Breyanzi Lisocabtagene maraleucel CD19 2L/3L+FL(TRANSCEND-FL)2 5/1 3L+CLL 1/2 TRANSCEND CLL ASCO Carvykti Abecma Evaluate BMS(BMY)13 Reblozyl Luspatercept TGF-EMA 1L MDS(COMMANDS)PDUFA 8/28 Sotyktu deucravacitinib TYK2 CD LATTICE-CD 2 Rinvoq upadacitinib JAK TNF-a IL-23 JAK 1L Sotyktu LPA1 PPF(IM027-040)2 FDA Ofev nintedanib Esbriet pirfenidone Esbriet PPF 1/3 1 BMS Horizon LPA1 HZN-825 2 Camzyos mavacamten myosin 2023/6/16 SRT eligible(VALOR)Targeting fibrosis:mechanisms and clinical trials Manyu Zhao BMS(BMY)14 04 Sanofi15(SNY)BTKi 2024 BTKi efficacy FDA Sarclisa Isatuximab CD38 1L MM(IMROZ)2023H2 CD38 Darzalex daratumumab 2015 2018 1L Sarclisa 2020 RRMM Darzalex 2020 Sarclisa 3 NCT05405166 2024 5 Darzalex COPD Sarclisa 2024 Sanofi Tolebrutinib BTK 2023H2 GEMINI 1/2(event-driven)class effect/3 FDA 5/17 fenebrutinib RMS II remibrutinib BTK 16 Fitusiran(SAR-439774 ATIII)2023 A/B 3 Topline 12 3 ATLAS-PEDS NCT03974113 8/9 Alnylam RNAi 4:1 3 Beyfortus(RSV F protein)2023 Kevzara(Sarilumab IL-6R)2023 Tusamitamab ravtansine CEACAM5-ADC 2023H2 2/3L NSCLC 2024 Fitusiran 3 ATLAS-INH Fitusiran 3 ATLAS-AB(SNY)BTKi17 05 Amgen18(AMGN)/TEZSPIRE(tezepelumab TSLP 2 CSU Topline 2023 2023/3/7 Dupixent CSU FDA PDUFA 2023/10/22 CSU BTK remibrutinib 3 NCT05795153 2024 remibrutinib BTK COPD 2 2024H1 Ann Allergy Asthma Immunol Current and EmergingTreatments for Chronic Spontaneous Urticaria Kirti J.Johal CSU modality 19 Tarlatamab DLL3xCD3 2023H2 DeLLphi-301 SCLC 2 PD-1 AMG404 1 2L+SCLC 1b Amgen AMG119 DLL3 CAR-T SCLC 1 DLL3 news medical DLL3(AMGN)/20 LUMAKRAS Sotorasib KRAS G12C 2023H2 LUMAKRAS Vectibix panitumumab EGFR 3L 3 CodeBreaK 300 SOC NSCLC ASCO SOC CRC ASCO Mirati Sotorasib Adagrasib(AMGN)/21 BLINCYTO blinatumomab CD19xCD3 2023H2 Ph-negative B-ALL MRD-Xaluritamig AMG 509 STEAP1xCD3 2023H2 mCRPC 1 Xencor XmAb 2+1 1 2 3 1400 ABP 654 IL-12/23 2023H1 3 ABP 938 PGF/VEGF-A 2023H1 3 Xencor XMAB(AMGN)/22 06 Gilead23 HIV(GILD)HIV Etrumadenant A2bR/A2aR 2023H2 mCRPC 2 ARC-6 2023H2 mCRC 2 ARC-9 Magrolimab CD47 1L HR MDS ENHANCE 2023H2 3 Lenacapavir HIV capsid bictegravir HIV ARTISTRY-1 2023H2 2 Bulevirtide Hepcludex NTCP 2023H2 HDV 2 Trodelvy AZ Dato-DXD 24 25 2019 2018 2017 2016 2015 1.6 6 20%5%20%-5%+5%5%2.A 500 10%-10%10%10%26 2017 7 1/27 600 N1 9+86 21 68761616+86 21 68767880400-8888-128
展开阅读全文